However, SGLT2 inhibitors showed no advantage over placebo in reducing the risk of MI and stroke (MI: RR 0.92; 95% CI: 0.83–1.01; p for heterogeneity 0.44; I2 = 0%; p = 0.06 and stroke: RR 1.07; 95% CI: 0.94–1.22; p for heterogeneity 0.61; I2 = 0%; p = 0.29) (Supplementary Figure 1). This evidence concerns the gene SLC5A2 and stroke disorder.